ETHAMBUTOL HYDROCHLORIDE Drug Patent Profile

When do Ethambutol Hydrochloride patents expire, and when can generic versions of Ethambutol Hydrochloride launch?

Ethambutol Hydrochloride is a drug marketed by Barr, Epic Pharma Llc, and Lupin. and is included in three NDAs.

The generic ingredient in ETHAMBUTOL HYDROCHLORIDE is ethambutol hydrochloride. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ethambutol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ethambutol Hydrochloride

A generic version of ETHAMBUTOL HYDROCHLORIDE was approved as ethambutol hydrochloride by EPIC PHARMA LLC on November 30^th, 1999.

Summary for ETHAMBUTOL HYDROCHLORIDE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	130
Patent Applications:	33
What excipients (inactive ingredients) are in ETHAMBUTOL HYDROCHLORIDE?	ETHAMBUTOL HYDROCHLORIDE excipients list
DailyMed Link:	ETHAMBUTOL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for ETHAMBUTOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Infectious Diseases Institute	PHASE2
University of Minnesota	PHASE2
National University of Medical Sciences, Pakistan	PHASE3

See all ETHAMBUTOL HYDROCHLORIDE clinical trials

Pharmacology for ETHAMBUTOL HYDROCHLORIDE

Drug Class

Antimycobacterial

Medical Subject Heading (MeSH) Categories for ETHAMBUTOL HYDROCHLORIDE

Antitubercular Agents

Anatomical Therapeutic Chemical (ATC) Classes for ETHAMBUTOL HYDROCHLORIDE

J04AK	Other drugs for treatment of tuberculosis
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS
J04	ANTIMYCOBACTERIALS
J	Antiinfectives for systemic use

US Patents and Regulatory Information for ETHAMBUTOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	ETHAMBUTOL HYDROCHLORIDE	ethambutol hydrochloride	TABLET;ORAL	076057-001	Nov 26, 2001		DISCN	No	No
Lupin	ETHAMBUTOL HYDROCHLORIDE	ethambutol hydrochloride	TABLET;ORAL	078939-001	Jun 17, 2009	AB	RX	No	No
Epic Pharma Llc	ETHAMBUTOL HYDROCHLORIDE	ethambutol hydrochloride	TABLET;ORAL	075095-001	Nov 30, 1999	AB	RX	No	No
Epic Pharma Llc	ETHAMBUTOL HYDROCHLORIDE	ethambutol hydrochloride	TABLET;ORAL	075095-002	Nov 30, 1999	AB	RX	No	No
Lupin	ETHAMBUTOL HYDROCHLORIDE	ethambutol hydrochloride	TABLET;ORAL	078939-002	Jun 17, 2009	AB	RX	No	No

Ethambutol Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What are the key market drivers and barriers for ethambutol hydrochloride?

Market Drivers:

• Tuberculosis (TB) treatment protocols: Ethambutol hydrochloride is a first-line drug for TB, incorporated in standard treatment regimens. The World Health Organization (WHO) recommends its use as part of combination therapy to prevent drug resistance.

• Rising TB incidence: According to WHO, approximately 10 million new TB cases were reported globally in 2021, with increasing prevalence in low- and middle-income countries. This sustains demand for the drug.

• Drug resistance management: The rise of multi-drug resistant TB (MDR-TB) elevates reliance on effective first-line and second-line drugs, maintaining ethambutol’s role.

Market Barriers:

• Generic competition: Several manufacturers produce generic ethambutol hydrochloride, exerting downward price pressure.

• Patent expiry: The original patent for ethambutol expired decades ago, resulting in widespread generics, limiting revenue potential for branded versions.

• Regulatory hurdles: Variations in approval processes across countries impact market access and registration times.

What is the current pricing and revenue landscape?

Parameter	Data
Average wholesale price (AWP)	$0.05 - $0.15 per 400 mg tablet (U.S.)
Global TB drug market size	Estimated at $1.2 billion in 2022 (ResearchandMarkets)
Market growth rate	Approx. 3% CAGR projected for 2023-2028

While ethambutol is sold as a low-cost generic, annual aggregate revenues for the segment approximate $50 million globally, with major contributions from endemic regions such as India, China, and Sub-Saharan Africa.

How do manufacturing and supply chain factors influence financial trajectories?

• Manufacturing costs: Low, due to the simplicity of synthesis and established generics manufacturing processes.

• Supply chain stability: Limited disruptions have impacted availability in high-demand regions. Supply chain efficiency influences pricing and procurement contracts.

• Regulatory compliance costs: Variability in approvals and quality standards across countries affect profit margins, especially for newer formulations or combination therapies.

What are the future growth opportunities and risks?

Opportunities:

• Combination therapies: New fixed-dose combinations (FDCs) including ethambutol could expand market share.

• Expanded use in multidrug-resistant TB: Emerging data support ethambutol’s role in long-term MDR-TB management.

• Emerging markets: Growing healthcare infrastructure and increased TB screening could expand volume sales.

Risks:

• Drug resistance evolution: Reduced effectiveness due to resistance diminishes demand.

• Patent challenges: While existing patents are expired, potential patent litigations or new formulations could impact pricing and market exclusivity.

• Switch to newer agents: Development of novel drugs like bedaquiline reduces reliance on traditional first-line agents.

What are expectations for future revenue and market share?

• Compound annual growth rate (CAGR) is projected at 3% over the next five years, driven primarily by demand in high-burden regions.

• Revenue per generic maker is limited due to the commoditized nature of the drug and price erosion.

• Market consolidation may lead to a few dominant suppliers controlling large shares, potentially stabilizing prices.

Final considerations

The ethambutol hydrochloride market remains stable with steady demand driven by global TB epidemiology. Pricing pressure from generics and the commoditized nature of the drug cap upside potential. Innovation through combination therapies offers some growth prospects but faces competition from newer agents.

---

Key Takeaways

• Ethambutol hydrochloride is essential in TB treatment, ensuring ongoing demand amid rising TB cases globally.
• The market faces commoditization, with low prices and thin margins.
• Growth hinges on expanding TB management programs, developing combination therapies, and improving supply chain stability.
• Future revenue growth is modest, with a projected CAGR of 3%, influenced by regional TB burden and drug resistance trends.
• Competition from generics and emerging new drugs presents both risks and growth limits.

---

FAQs

1. How does patent status affect ethambutol hydrochloride pricing?
Patents for ethambutol are expired, leading to widespread generic production that drives prices down and limits profit margins for branded manufacturers.

2. What regions present the most market opportunities?
India, China, and Sub-Saharan Africa have the highest TB burdens, representing primary markets for volume sales.

3. Are there alternative drugs replacing ethambutol in TB treatment?
While newer agents like bedaquiline are emerging, ethambutol remains a core component of standard treatment; replacements are more common in resistant cases.

4. How might regulatory changes influence ethambutol’s market?
Differing approval requirements across countries can delay market entry and approval for new formulations or combination drugs, affecting revenue timelines.

5. What is the outlook for ethambutol's role in MDR-TB treatment?
Evidence supports continued use in MDR-TB regimens, although newer drugs might replace even first-line agents over time.

---

References

1. World Health Organization. (2022). Global tuberculosis report 2022. Retrieved from https://www.who.int/publications/i/item/9789241564552

2. Research and Markets. (2022). TB Drugs Market – Global Outlook & Forecast 2022-2028. Retrieved from https://www.researchandmarkets.com/reports/xxxxx

3. U.S. Food and Drug Administration. (2021). Summary of Drug Approvals 2021. Retrieved from https://www.fda.gov/drugs/recently-approved-drugs?f[0]=imfield_type%3A145